Stock PRN PROFOUND MEDICAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Profound Medical Corp.

Equities

PRN

CA74319B5027

Delayed Toronto S.E.
Other stock markets
 02:10:22 2024-05-09 pm EDT 		5-day change 1st Jan Change
10.65 CAD +3.30% Intraday chart for Profound Medical Corp. +6.39% -4.05%
May. 06 Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer MT
May. 06 Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH" MT

Evolution of the average Target Price on Profound Medical Corp.

Price target over the last 5 years

History of analyst recommendation changes

e.gKrylC5d2WsLY5bGl3ZRtXOk6TsqQE2EtE3pONhWwIo.-fDD0BszjypZJsCDxhklwjaSkUtHFAHo_SiQQeAjpv7pz6PEdx-QG10Rww~4d079396061bcd4efaa5f0e88de538ec

Analyst Recommendations on Profound Medical Corp.

Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating MT
Stifel Starts Profound Medical With Hold Rating, $11 Price Target MT
North American Morning Briefing : Mood Lifted on Hopes Rate-Hike Cycle Has Peaked DJ
North American Morning Briefing : Concerns About Inflation, Interest Rates Persist DJ
Raymond James Downgrades Profound Medical to Outperform From Strong Buy MT
Alliance Global Partners Adjusts Price Target on Profound Medical to $15.75 From $13.15, Maintains Buy Rating MT
TD Cowen Adjusts Profound Medical Price Target to $18 From $14, Maintains Outperform Rating MT
Profound Medical Brief: Adds FARP Study "Provides Level 1 evidence that focal therapy with TULSA has a lower complication rate compared to RALP" MT
Jefferies Downgrades Profound Medical to Hold From Buy, Adjusts Price Target to $10 From $5.50 MT
Cowen Adjusts Profound Medical's Price Target to $14 from $28, Keeps Outperform Rating MT
Raymond James Downgrades Profound Medical to Outperform from Strong Buy, Adjusts Price Target to $23 from $28 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
10.31 CAD
Average target price
12.5 CAD
Spread / Average Target
+21.24%
High Price Target
12.5 CAD
Spread / Highest target
+21.24%
Low Price Target
12.5 CAD
Spread / Lowest Target
+21.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Profound Medical Corp.

Alliance Global Partners
Stifel Nicolaus
Raymond James
TD Cowen
Jefferies & Co.
Cowen

Ratings for Profound Medical Corp.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PRN Stock
  4. Consensus Profound Medical Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW